BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1237@pharmaconomics
DTSTAMP:20260707T025908Z
DTSTART;VALUE=DATE:20260611
DTEND;VALUE=DATE:20260612
SUMMARY:HCM Phase 3 — sovleplenib
DESCRIPTION:Phase 3 trial results for sovleplenib in warm antibody autoimmune hemolytic anemia are due Jun 11\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1648257/000164825726000039/hcm-20260612xex99d1.htm\n\nTrack it: https://pharmaconomics.com/e/1237
URL:https://pharmaconomics.com/e/1237
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:HCM catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR